

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

TECHNOLOGY APPRAISAL PROGRAMME

Equality impact assessment – Scoping

STA Sacituzumab govitecan for treating unresectable locally advanced or metastatic triple-negative breast cancer after two or more therapies

The impact on equality has been assessed during this appraisal according to the principles of the NICE Equality scheme.

1. Have any potential equality issues been identified during the scoping process (draft scope consultation and scoping workshop discussion), and, if so, what are they?

No equalities issues were raised. However, it was noted that the prevalence of triple-negative breast cancer is higher among people of African ancestry than among white people. Consequently, guidance that restricts the use of sacituzumab govitecan may disproportionately impact black people.

2. What is the preliminary view as to what extent these potential equality issues need addressing by the Committee?

The committee cannot address issues of prevalence.

3. Has any change to the draft scope been agreed to highlight potential equality issues?

No

4. Have any additional stakeholders related to potential equality issues been identified during the scoping process, and, if so, have changes to the matrix been made?
No.

Approved by Associate Director (name):Janet Robertson.....

Date: 16 August 2021